Format

Send to

Choose Destination
BMC Public Health. 2016 Mar 2;16:212. doi: 10.1186/s12889-016-2783-9.

Bio-behavioural HIV and STI surveillance among men who have sex with men in Europe: the Sialon II protocols.

Author information

1
Veneto Region - Department of Health, CReMPE - Regional Coordination Centre for European Project Management, the Verona University Hospital, Verona, Italy. gios.lorenzo@gmail.com.
2
Veneto Region - Department of Health, CReMPE - Regional Coordination Centre for European Project Management, the Verona University Hospital, Verona, Italy. massimo.mirandola@regione.veneto.it.
3
Department of Pathology, Infectious Diseases Section, the Verona University Hospital - Veneto Region, Verona, Italy. massimo.mirandola@regione.veneto.it.
4
Department of Reproductive Health & Research, World Health Organization, Geneva, Switzerland. toskini@who.int.
5
Department for Infectious Diseases Epidemiology, Robert Koch-Institute, Berlin, Germany. MarcusU@rki.de.
6
Department for Infectious Diseases Epidemiology, Robert Koch-Institute, Berlin, Germany. Dudareva-VizuleS@rki.de.
7
Centre for Health Research, University of Brighton, Brighton, UK. n.s.sherriff@brighton.ac.uk.
8
Veneto Region - Department of Health, CReMPE - Regional Coordination Centre for European Project Management, the Verona University Hospital, Verona, Italy. michele.breveglieri@ospedaleuniverona.it.
9
Veneto Region - Department of Health, CReMPE - Regional Coordination Centre for European Project Management, the Verona University Hospital, Verona, Italy. martina.furegato@ospedaleuniverona.it.
10
Institut Catala d'Oncologia (ICO), Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agencia de Salut Publica de Catalunya (ASPC), Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. cfolch@iconcologia.net.
11
Institut Catala d'Oncologia (ICO), Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agencia de Salut Publica de Catalunya (ASPC), Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. lfserret@iconcologia.net.
12
Institut Catala d'Oncologia (ICO), Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agencia de Salut Publica de Catalunya (ASPC), Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. amontoliu@iconcologia.net.
13
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. cnoestlinger@itg.be.
14
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. Wvandenberghe@itg.be.
15
Department of Monitoring and Evaluation, Public Health Agency of Sweden, Solna, Sweden. sharon.kuhlmann-b@folkhalsomyndigheten.se.
16
Department of Monitoring and Evaluation, Public Health Agency of Sweden, Solna, Sweden. inga.velicko@folkhalsomyndigheten.se.
17
Institute of Hygiene and Tropical Medicine & GHTM, Universidade Nova de Lisboa, Lisbon, Portugal. smfdias@yahoo.com.
18
Centro Operativo AIDS, Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, Istituto Superiore di Sanità, Rome, Italy. barbara.suligoi@iss.it.
19
Centro Operativo AIDS, Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, Istituto Superiore di Sanità, Rome, Italy. vincenza.regine@iss.it.
20
NRC for HIV/AIDS, Slovak Medical University, Bratislava, Slovak Republic. danica.stanekova@szu.sk.
21
Department of Epidemiology, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland. mrosinska@pzh.gov.pl.
22
Centre for Communicable Diseases and AIDS, Vilnius, Lithuania. saulius.caplinskas@ulac.lt.
23
National Institute of Public Health, Ljubljana, Slovenia. irena.klavs@nijz.si.
24
National Reference Laboratory of HIV, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria. ivoalexiev@yahoo.com.
25
National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania.

Abstract

BACKGROUND:

Globally, the HIV epidemic continues to represent a pressing public health issue in Europe and elsewhere. There is an emerging and progressively urgent need to harmonise HIV and STI behavioural surveillance among MSM across European countries through the adoption of common indicators, as well as the development of trend analysis in order to monitor the HIV-STI epidemic over time. The Sialon II project protocols have been elaborated for the purpose of implementing a large-scale bio-behavioural survey among MSM in Europe in line with a Second Generation Surveillance System (SGSS) approach.

METHODS/DESIGN:

Sialon II is a multi-centre biological and behavioural cross-sectional survey carried out across 13 European countries (Belgium, Bulgaria, Germany, Italy, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the UK) in community settings. A total of 4,966 MSM were enrolled in the study (3,661 participants in the TLS survey, 1,305 participants in the RDS survey). Three distinct components are foreseen in the study protocols: first, a preliminary formative research in each participating country. Second, collection of primary data using two sampling methods designed specifically for 'hard-to-reach' populations, namely Time Location Sampling (TLS) and Respondent Driven Sampling (RDS). Third, implementation of a targeted HIV/STI prevention campaign in the broader context of the data collection.

DISCUSSION:

Through the implementation of combined and targeted prevention complemented by meaningful surveillance among MSM, Sialon II represents a unique opportunity to pilot a bio-behavioural survey in community settings in line with the SGSS approach in a large number of EU countries. Data generated through this survey will not only provide a valuable snapshot of the HIV epidemic in MSM but will also offer an important trend analysis of the epidemiology of HIV and other STIs over time across Europe. Therefore, the Sialon II protocol and findings are likely to contribute significantly to increasing the comparability of data in EU countries through the use of common indicators and in contributing to the development of effective public health strategies and policies in areas of high need.

PMID:
26935752
PMCID:
PMC4776381
DOI:
10.1186/s12889-016-2783-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center